In this study, GC7 treatment resulted in a decrease in pancreatic Th1 cells and a concurrent increase in pancreatic anti-inflammatory Treg cells, a result which is linked to a reduction in serum GAD65 antibody concentration and an overall delay in T1D onset [26]. The gene discussed is GAD2; the disease is type 1 diabetes mellitus.